![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RR Griffiths, SM Evans, JJ Guarino, JD Roache, WR Furman, I Liebson and EM Schwam
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
The effects of i.v. administered flumazenil (3.0 mg) were studied in healthy male subjects who received pretreatment with p.o. placebo or lorazepam. The duration of placebo or lorazepam (3.0 mg single p.o. daily dose) pretreatment before a flumazenil or placebo injection was 1, 3, 7 or 14 days in four sequential groups of subjects. Initial administration of lorazepam produced a classic sedative profile of effects on various psychomotor/behavioral performance, observer-rated and subject-rated measures. Tolerance to repeated daily administration of lorazepam was suggested by a progressive diminution of performance disrupting effects. In subjects pretreated with placebo, flumazenil increased subject-ratings of dizziness over preinjection ratings. Flumazenil produced an immediate reversal of lorazepam effects in subjects who were not tolerant to lorazepam (1- and 3-day pretreatment groups). Flumazenil did not precipitate withdrawal symptoms in subjects who received a single administration of lorazepam. Precipitated withdrawal symptoms were evident after 3 and 7 days of lorazepam pretreatment, and there was a tendency toward precipitated withdrawal symptoms (that included one panic attack) after 14 days of lorazepam pretreatment. Precipitated withdrawal was characterized by an elevation in subject-rated symptoms including dizziness, tenseness, tachycardia, perceptual disturbance and sweating. Symptoms were maximal immediately after injection, usually mild in severity and usually resolved within 1 hr. There was no evidence of precipitated withdrawal on psychomotor/behavioral performance or observer ratings. The present study provides the strongest human experimental evidence to date that flumazenil can precipitate withdrawal symptoms after a history of repeated benzodiazepine exposure.
This article has been cited by other articles:
|
|
 |
|
  L. R. McMahon, L. R. Gerak, and C. P. France Efficacy and the Discriminative Stimulus Effects of Negative GABAA Modulators, or Inverse Agonists, in Diazepam-Treated Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 907 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. V. Tcheremissine, S. D. Lane, L. M. Lieving, H. M. Rhoades, S. Nouvion, and D. R. Cherek Individual differences in aggressive responding to intravenous flumazenil administration in adult male parolees J Psychopharmacol, November 1, 2005; 19(6): 640 - 646. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Park Rescue Is Stressful Anesth. Analg., August 1, 2002; 95(2): 263 - 265. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Smith and W. K. Bickel Flumazenil Discrimination by Humans under a Two-Response and a Novel-Response Procedure J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1257 - 1268. [Abstract] [Full Text]
|
|
|
|
|
|
M.A. Bernik, C. Gorenstein, and A.H.G. Vieira Filho Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users J Psychopharmacol, January 1, 1998; 12(2): 146 - 150. [Abstract] [PDF]
|
|
|
|
|
|
A. Patat, M.C. Perault, B. Vandel, Ph. Danjou, S. Brohier, I. Zieleniuk, and P. Rosenzweig Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers J Psychopharmacol, January 1, 1995; 9(2): 91 - 101. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
